Physician profile
Robert Ae Summerfield
NPI 1215919659
$10,246.86
in general payments reported to CMS, 2019-2025
53 companies · $3,299 in 2025
The $3,299 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $517 · 2021: $1,501 · 2022: $442 · 2023: $831 · 2024: $2,448 · 2025: $3,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,570 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,570.37 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.23 | 2021-2025 | Ubrelvy, Qulipta |
| Sk Life Science, INC. | $1,112.34 | 2020-2025 | Xcopri |
| Argenx US, INC. | $947.91 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $917.59 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Emd Serono, INC. | $500.14 | 2019-2025 | |
| Lilly USA, LLC | $488.50 | 2021-2025 | Kisunla, Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $420.80 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $406.29 | 2019-2022 | |
| Genentech USA, INC. | $364.48 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $302.67 | 2020-2025 | Ingrezza |
| Tg Therapeutics, INC. | $295.07 | 2023-2025 | |
| Biogen, INC. | $294.79 | 2021-2025 | Tysabri, Vumerity |
| Eisai INC. | $246.63 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $161.24 | 2019-2021 | |
| Greenwich Biosciences, INC. | $156.04 | 2019-2021 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $155.19 | 2020-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $143.03 | 2021-2025 | Nuplazid |
| Celgene Corporation | $138.09 | 2021-2024 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $135.28 | 2021 | |
| Adamas Pharmaceuticals, INC. | $131.46 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.41 | 2024-2025 | Hyqvia |
| Amneal Pharmaceuticals LLC | $117.81 | 2019-2025 | Crexont, Rytary |
| Upsher-Smith Laboratories LLC | $115.73 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $100.01 | 2025 | Inbrija, Xeomin |
| Acorda Therapeutics, INC | $99.94 | 2019 | |
| Pfizer INC. | $84.92 | 2023-2025 | |
| Banner Life Sciences, LLC | $84.62 | 2024 | |
| Mdd US Operations, LLC | $83.20 | 2022-2025 | Qelbree |
| Lundbeck LLC | $78.49 | 2024-2025 | Vyepti |
| Livanova USA, INC. | $76.97 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $54.21 | 2021-2024 | Aimovig |
| Jazz Pharmaceuticals INC. | $53.20 | 2024-2025 | |
| Csl Behring | $51.78 | 2025 | Hizentra |
| Medtronic, INC. | $48.97 | 2025 | Intellis Adaptivestim |
| Genzyme Corporation | $48.95 | 2021 | |
| Allergan, INC. | $48.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.29 | 2020-2021 | |
| Cala Health, INC. | $45.18 | 2025 | Cala Kiq |
| Averitas Pharma INC. | $41.06 | 2024 | Qutenza |
| Boston Scientific Corporation | $34.41 | 2019-2022 | |
| Cycle Pharmaceuticals INC | $34.13 | 2025 | Tascenso Odt, Bafiertam |
| Vanda Pharmaceuticals INC. | $33.73 | 2024 | Ponvory |
| Ani Pharmaceuticals, INC. | $31.37 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $29.22 | 2025 | Ultomiris |
| Janssen Biotech, INC. | $26.01 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $23.81 | 2025 | |
| Grifols USA, LLC | $23.01 | 2024 | Gamunex-C |
| Axsome Therapeutics, INC. | $22.73 | 2025 | Symbravo |
| Aucta Pharmaceuticals, INC. | $21.50 | 2025 | Motpoly Xr |
| Tanabe Pharma America, INC. | $17.50 | 2021 | |
| Kyowa Kirin, INC. | $15.21 | 2024 | Nourianz |
| Inspire Medical Systems, INC. | $14.35 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Summerfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.